

Using the ECHO Model to Expand Access to Care and Treatment for HIV and Viral Hepatitis

Karla Thornton, MD, MPH
Professor, Infectious Diseases
University of New Mexico
Associate Director, ECHO Institute
kthornton@salud.unm.edu

11/3/17

Conflicts of Interest

- I have no conflicts of interest to disclose



Moving Knowledge Instead of Patients

Objectives

- Describe the history and development of Project ECHO
- Describe how Project ECHO has impacted care for persons living with HIV and hepatitis C
- Discuss the replication of the ECHO model nationally and internationally

Hepatitis C in New Mexico (2004)



- Large geographic area, low population density
- Few health care providers and no specialists
- More than 35,000 reported HCV cases, < 5% had been treated
- Highest rate of chronic liver disease/cirrhosis

Hepatitis C Treatment in 2004

- Good News
 - Curable in 45-70% of cases
- Bad News
 - Severe side effects
 - Anemia 100%
 - Neutropenia >35%
 - Depression >25%
- No primary care clinicians treating HCV

Goals of Project ECHO

- Develop capacity to safely and effectively treat HCV in all areas of New Mexico and to monitor outcomes
- Develop a model to treat complex diseases in rural locations and developing countries

Methods



- Use technology to leverage scarce healthcare resources (specialty knowledge and expertise)
- Share “best practices” - reduce disparities by reducing variation in care
- Case based learning (learning by doing) to master complexity
- Web-based database to monitor outcomes

Arora S, Geppert CM, Kalishman S, et al: Acad Med. 2007 Feb;82(2): 154-60.

Project ECHO: Multidisciplinary Teams



ECHO Facilitators
Multidisciplinary Team
Infectious Diseases
Hepatology
Psychiatry
Pharmacy



ECHO Partners
Community Clinic
Primary Care Team



Steps

- Train physicians, nurses, pharmacists and their teams in HCV care
- Conduct teleECHO clinics – “Knowledge Network”
- Initiate case-based guided practice – “Learning loops”
- Collect data and monitor outcomes centrally



Stop Recording

Total non-video participants: 2



Mute Stop Video


Invite Participants 14 Share Screen Chat Stop Recording

Leave Meeting



Learning Loops

- Interactive Learning Environment
- Co-management of Cases
- Learning by doing
- Learning from didactics
- Learning from each other
- Collaborative Problem Solving



ECHO vs. Telemedicine

TeleECHO™ Clinic



Expert hub team

ECHO supports
community based
primary care teams



Learners at spoke site

Patients reached with specialty
knowledge and expertise



Traditional Telemedicine



Specialist manages patient remotely



Benefits to Clinicians and Teams

- No cost continuing education credits
- Professional interaction with colleagues with similar interest
 - Less isolation with improved recruitment and retention
- A mix of work and learning
- Access to specialty consultation with infectious diseases, hepatology, psychiatry, addiction specialist, pharmacist

Arora S, Thornton K, et al. Hepatology. 2010 Sept; 52(3):1124-33.

Benefits to Communities

- Increased access to HCV treatment
- Decreased HCV related mortality and suffering
- Training of the local workforce

Project ECHO Clinicians HCV Knowledge, Skills and Self-Efficacy

scale: 1 = none or no skill at all 7= expert-can teach others

Community Clinicians n=25	Before Participation Mean (SD)	Today Mean (SD)	Paired Difference Mean (SD) (p-value)	Effect Size for the Change
1. Ability to identify suitable candidates for the treatment of HCV.	2.8 (1.2)	5.6 (0.8)	2.8 (1.2) (<0.0001)	2.4
2. Ability to assess severity of liver disease in patients with Hepatitis C.	3.2 (1.2)	5.5 (0.9)	2.3 (1.1) (<0.0001)	2.1
3. Ability to treat HCV patients and manage side effects.	2.0 (1.1)	5.2 (0.8)	3.2 (1.2) (<0.0001)	2.6

Project ECHO Clinicians HCV Knowledge, Skills and Self-Efficacy

scale: 1 = none or no skill at all 7= expert-can teach others

Community Clinicians n=25	Before Participation Mean (SD)	Today Mean (SD)	Paired Difference Mean (SD) (p-value)	Effect Size for the Change
4. Ability to assess and manage psychiatric co-morbidities in patients with Hepatitis C.	2.6 (1.2)	5.1 (1.0)	2.4 (1.3) (<0.0001)	1.9
5. Serve as local consultant within my clinic and in my area for HCV questions and issues.	2.4 (1.2)	5.6 (0.9)	3.3 (1.2) (<0.0001)	2.8
6. Ability to educate and motivate HCV patients.	3.0 (1.1)	5.7 (0.6)	2.7 (1.1) (<0.0001)	2.4

ORIGINAL ARTICLE

Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers

Sanjeev Arora, M.D., Karla Thornton, M.D., Glen Murata, M.D.,
Paulina Deming, Pharm.D., Summers Kalishman, Ph.D., Denise Dion, Ph.D.,
Brooke Parish, M.D., Thomas Burke, B.S., Wesley Pak, M.B.A.,
Jeffrey Dunkelberg, M.D., Martin Kistin, M.D., John Brown, M.A.,
Steven Jenkushy, M.D., Miriam Komaromy, M.D., and Clifford Qualls, Ph.D.

ABSTRACT

BACKGROUND

The Extension for Community Healthcare Outcomes (ECHO) model was developed to improve access to care for underserved populations with complex health problems such as hepatitis C virus (HCV) infection. With the use of video-conferencing technology, the ECHO program trains primary care providers to treat complex diseases.

METHODS

We conducted a prospective cohort study comparing treatment for HCV infection at the University of New Mexico (UNM) HCV clinic with treatment by primary care clinicians at 21 ECHO sites in rural areas and prisons in New Mexico. A total of 407 patients with chronic HCV infection who had received no previous treatment for the infection were enrolled. The primary end point was a sustained virologic response.

RESULTS

A total of 57.5% of the patients treated at the UNM HCV clinic (84 of 146 patients) and 58.2% of those treated at ECHO sites (152 of 261 patients) had a sustained viral response (difference in rates between sites, 0.7 percentage points; 95% confidence interval, -9.2 to 10.7; $P=0.89$). Among patients with HCV genotype 1 infection, the rate of sustained viral response was 45.8% (38 of 83 patients) at the UNM HCV clinic and 49.7% (73 of 147 patients) at ECHO sites ($P=0.57$). Serious adverse events occurred in 13.7% of the patients at the UNM HCV clinic and in 6.9% of the patients at ECHO sites.

CONCLUSIONS

The results of this study show that the ECHO model is an effective way to treat HCV infection in underserved communities. Implementation of this model would allow other states and nations to treat a greater number of patients infected with HCV than they are currently able to treat. (Funded by the Agency for Healthcare Research and Quality and others.)

From the Department of Internal Medicine (S.A., K.T., G.M., P.D., S.K., D.D., B.P., T.B., W.P., M. Kistin, J.B., M. Komaromy) and the Clinical and Translational Science Center (C.Q.), University of New Mexico; and Presbyterian Healthcare Services, Adult and Geriatric Behavioral Health Clinic (S.J.) — both in Albuquerque; and the Department of Internal Medicine, University of Iowa, Iowa City (J.D.). Address reprint requests to Dr. Arora at Project ECHO, 1 University of New Mexico, MSC07-4245, Albuquerque, NM 87131, or at sarora@salud.unm.edu.

This article (10.1056/NEJMoa1009370) was published on June 1, 2011, at NEJM.org.

N Engl J Med 2011;364:2199-207.

Copyright © 2011 Massachusetts Medical Society.

Study Design

- Prospective Cohort
- Study sites
 - Intervention (ECHO)
 - Community-based clinics:16
 - New Mexico Department of Corrections:5
 - Control
 - University of New Mexico Hepatitis C Clinic
- Principal Endpoint
 - Sustained viral response (SVR): no detectable virus 6 months after completion of treatment

Arora S, Thornton K, et al.. N Engl J Med. 2011 Jun; 364:2199-207.

SVR According to Genotype and Site

HCV Genotype	ECHO sites	UNM HCV Clinic	P Value
All Genotypes	58.2%	84/146 (57.5%)	0.89
Genotype 1	73/147 (49.7%)	38/83 (45.8%)	0.57
Genotype 2 or 3	78/112 (69.6%)	42/59 (71.2%)	0.83


Arora S, Thornton K, et al.. N Engl J Med. 2011 Jun; 364:2199-207.

Conclusion


Primary care clinicians deliver hepatitis C care under the aegis of Project ECHO that is as safe and effective as that given in a university clinic.

Arora S, Thornton K, et al.. N Engl J Med. 2011 Jun; 364:2199-207.

Hepatitis C Treatment in New Mexico



Expanding the Definition of Underserved Population



Disease Selection


- Common diseases
- Management is complex
- Evolving treatments and medicines
- High societal impact
- Serious outcomes of untreated disease
- Improved outcomes with disease management


Successful Expansion into Multiple Diseases

MON	TUE	WED	THURS	FRI
<u>Rheumatology</u> <ul style="list-style-type: none"> • Bankhurst 	<u>HBV</u> <ul style="list-style-type: none"> • Thornton 	<u>Community Health Workers</u> <ul style="list-style-type: none"> • CHW Team 	<u>CDC Good Health and Wellness in Indian Country</u> <ul style="list-style-type: none"> • Struminger 	<u>Opioid Addiction</u> <ul style="list-style-type: none"> • Komaromy
<u>Tuberculosis</u> <ul style="list-style-type: none"> • Burgos 	<u>Bone Health</u> <ul style="list-style-type: none"> • Lewiecki 	<u>Endocrinology & Diabetes</u> <ul style="list-style-type: none"> • Bouchonville 	<u>Chronic Pain and Opioid Management</u> <ul style="list-style-type: none"> • Commerci 	<u>Nurse Practitioner/ Certified Midwife Primary Care</u> <ul style="list-style-type: none"> • Van Roper
<u>Cardiology</u> <ul style="list-style-type: none"> • Achrekar, Anderson & Yatskowitz 	<u>Crisis Intervention for Community Policing Agencies</u> <ul style="list-style-type: none"> • Duhigg 	<u>HIV</u> <ul style="list-style-type: none"> • Iandiorio 	<u>Prison Peer Education Program</u> <ul style="list-style-type: none"> • Thornton 	<u>Integrated Addictions and Psychiatry (IAP)</u> <ul style="list-style-type: none"> • Komaromy
<u>Reproductive Health</u> <ul style="list-style-type: none"> • Singh 	<u>Seizures and Spells</u> <ul style="list-style-type: none"> • Imerman 	<u>Hepatitis C (HCV)</u> <ul style="list-style-type: none"> • Arora & Thornton 	<u>HIV/ HCV Corrections</u> <ul style="list-style-type: none"> • Iandiorio & Thornton 	<u>Antimicrobial Stewardship</u> <ul style="list-style-type: none"> • Brett, Irizarry & Mercier

Successful Expansion into Multiple Health Conditions/Areas

- > 50 health conditions (140 hubs)
- Antimicrobial Stewardship
- Quality Improvement
- CIT (Crisis Intervention Team)
- Education/Assistive Technologies







ECHO Hubs and Superhubs: Global



HIV and Viral Hepatitis

ECHO activities globally





ECHO HIV Hubs: Global




Updated: Sep 13 2017

What is ECHO?

Extension for Community Health Outcomes




HIV ECHO Distribution & Capacity Building



*Yellow dots = locations where an ECHO site trainee moved and continued to participate

First ECHO Launch in Africa

Namibia HIV - November 2015



Ministry of Health and Social Services



Size:

318,261 sq mi

Population:

2.3 million people

HIV Prevalence:

Age 15-49 (14%)

230,000 people living with HIV

Challenges:

- Many remote areas, patients travel far
- Chronic shortage of doctors and nurses in public sector

Source: World Health Organization, African Health Observatory, Namibia, Health workforce

This is a royalty free image that can be used for your personal, corporate or education projects. It can not be resold or freely distributed, if you need an editable PowerPoint or Adobe Illustrator version of this map please visit www.bjdesign.com or www.mapsofordesign.com. This text can be cropped off. © Copyright Bruce Jones Design Inc. 2011

ECHO Consortium and Partners



Republic of Namibia Ministry of Health and Social Services



Centers for Disease
Control and
Prevention (CDC)

US Headquarters

CDC Namibia



Elizabeth Glaser
Pediatric AIDS
Foundation

EGPAF




International Training & Education
Center for Health Namibia



The University of New Mexico



University of Washington




First ECHO Session in Africa November 2015



Central Asia – Fall 2016

UNM and ICAP at Columbia University Collaborations



Central Asia

- Two weekly sessions held since Fall 2016 in Kazakhstan
 - Over 90 participants per session at 24 spoke sites
- Kyrgyzstan - 22 spokes
- Tajikistan implementing fall 2017

Kenya launch – Fall 2016

UNM and ICAP at Columbia University Collaborations

- Successful launch of regional hub with little support (less than 4 months after training)
- Ministry of Health fully on board
- Cases previously submitted to technical working group now are discussed in ECHO



Tanzania and Uganda – First Laboratory ECHOs

Launched November 23, 2016 and March 6, 2017



Tanzania Launch with guests from
Namibia and Kenya via Zoom



Official Uganda launch

RTQI ECHOs - Training of HIV rapid testers – quality improvement

African Society of Laboratory Medicine HIV Viral Load Scale Up Community of Practice



ECHO Hepatitis Hubs: Global



Georgia HCV Elimination Program



Expansion of ECHO in Georgia

- Blood Safety
- HCV Treatment in primary care and harm reduction centers
- HCV testing, counseling and linkage to care
- Infection Prevention and Control

Potential Benefits of the ECHO Model

- Improve Quality and Safety
- Rapid Learning and best-practice dissemination
- Reduce variations in care
- Access for Rural and Underserved Patients, reduced disparities
- Workforce Training and Force Multiplier
- Improve Professional Satisfaction/Retention
- Support Medical Home Model
- Cost Effective Care- Avoid Excessive Testing and Travel
- Prevent Cost of Untreated Disease (e.g.: liver transplant or dialysis)
- Integration of Public Health into treatment paradigm

Democratize Knowledge

Summary

- The ECHO model can be used effectively for education and workforce development in underserved areas
- Multiple successful pilots for HIV in Africa and Central Asia
- Capacity to treat HCV domestically impacted by use of the ECHO model
- Due to lack of funding, international viral hepatitis programs have been slower to start



Moving Knowledge Instead of Patients & Providers